Yinhua CNI HK Connect Innovative Drugs ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

National Healthcare Security Administration Adjusts 2026 Catalog Plan, Strengthening Market Expectations for Innovative Drugs

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

CMBC International and DBS Maintain Buy Rating for BeiGene

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

01177

Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, presented promising preclinical data for TQF6422, a monoclonal antibody aimed at obesity treatment, at the European Congress on Obesity 2026. The drug demonstrated significant fat reduction and muscle preservation in animal models, outperforming competitors. With a favorable safety profile and plans for clinical trials, TQF6422 is part of a broader weight-loss pipeline, including other innovative therapies. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy, with a target price of HK$8.70, reflecting confidence in its growth in the obesity treatment market.

Tip Ranks

SBP GROUP

Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline

01801

159316

159570

159506

159992

159849

520690

520880

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Tianhong CNI BIOMEDICINE ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

06160

Citic Securities has reaffirmed its Buy rating for BeOne Medicines Ltd (6160) as of May 12, setting a price target of HK$234.00, while the shares closed at HK$189.90. The analyst consensus for the stock is Strong Buy, with a target consensus of HK$254.33, indicating a potential upside of 33.93%. Additionally, DBS also maintains a Buy rating with a price target of HK$290.00.

BEONE MEDICINES

Beigene

BeOne Medicines

CITIC SEC

CITIC Securities Co., Ltd.

Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

159567

The Yinhua CNI HK Connect Innovative Drugs ETF (159567) received a net financing purchase of CNY 7.0121 million on May 19, with a net financing purchase of CNY 32.0927 million in the past week and CNY 18.4732 million in the past month. This ETF was listed on January 11, 2024, and is managed by Yinhua Fund, with the latest fund size being CNY 7.45 billion

同壁财经

On May 19th, the Yinhua CNI HK Connect Innovative Drugs ETF (159567) had a net financing purchase of RMB 7.0121 million, with a net financing purchase of RMB 32.0927 million in the past week

02513

02476

03986

06869

06613

02015

01209

09926

00175

01109

KNOWLEDGE ATLAS(02513) rose 9.33%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 878.5%. VGT(02476) rose 8.47%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 75.7%. LI AUTO-W(02015) fell 14.15%, with a trading turnover 3.6 Billion HKD, and a year-to-date rose 0.1%. CHINA RES MIXC(01209) fell 6.19%, with a trading turnover 346.3 Million HKD, and a year-to-date rose 6.7%.

- The Hang Seng Index decreased by 1.11%, with a year-to-date increase of 0.2%.  
- The Hang Seng Tech Index fell by 1.95%, reflecting a year-to-date decline of 12.2%.  
- Notable stock movements include Zhizhu's 9.33% increase and an 878.5% cumulative rise for the year, alongside Lixiang Auto's 14.15% drop with minimal year-to-date growth.

Top Gainers&Losers

KNOWLEDGE ATLAS

GIGADEVICE

YOFC

Lens

LI AUTO-W

CHINA RES MIXC

AKESO

GEELY AUTO

CHINA RES LAND

Top 5 HK Stock Gainers/Losers (>100B) (5.18)

688235

Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The highest price reached HKD 191.8, while the lowest dipped to HKD 183.3, ultimately closing with a slight decline of 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, with phase buying pressure building up again. The total trading volume reached HKD 748 million, maintaining an active range as a leading stock in the biotechnology sector, with sustained investor interest. On the news front, the global biotechnology sector has recently gained continuous attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines such as PD-1 and BTK inhibitors are expected to see significant growth in overseas markets, which remains an important logic for institutional investment. Additionally, the Hong Kong stock market has recently benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained stable near the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume continues to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue

Technical Forecast

WUXI BIO

WuXi Biologics

Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

GlaxoSmithKline plc

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Universal 800 Health Care ETF

Goldman Sachs

GS Hldg R

GSK plc Sponsored ADR

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medical centers. GSK will manage regulatory and quality oversight while SBP Group handles distribution and promotional activities. Bepirovirsen, an investigational treatment for chronic hepatitis B, aims to address a significant healthcare issue affecting 75 million people in China. The drug has received priority review and breakthrough designations in multiple countries. GSK's recent acquisition of SiranBio's therapy further supports its expansion into new treatment areas.

Pharmaceutical Business Review

Ionis Pharma

GSK and SBP Group team up to advance bepirovirsen launch in China

02509

603259

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

WUXI XDC

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

01952

Everest Medicines Ltd. announced that non-executive director Wei Fu has increased his stake by purchasing 660,000 shares for approximately HK$20.7 million, averaging HK$31.25 per share. This move reflects Fu's confidence in the company's future, with potential for further increases in holdings. However, the board advises caution to investors. The latest analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$55.00. Everest Medicines focuses on developing innovative medicines for unmet medical needs and has a market cap of HK$11.36B.

EVEREST MED

Everest Medicines Director and Major Shareholder Raises Stake in Company

Yinhua CNI HK Connect Innovative Drugs ETF(159567.SZ)